Latest Information Update: 27 Nov 2007
At a glance
- Originator Innogenetics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pulmonary oedema
Most Recent Events
- 28 Jun 2004 INNO 201 is available for partnering (http://www.innogenetics.com)
- 31 Dec 2001 Preclinical trials in Pulmonary oedema in Europe (unspecified route)